{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:11:38Z","timestamp":1788567098690,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hawthorn special extract WS 1442 has beneficial effects on the cardiovascular system. Experimental studies have shown an antiarrhythmic effect of the substance. In the present study, we investigated antiarrhythmic effects of WS 1442 compared with magnesium\/potassium in a large collective of outpatients. Using the IQVIA Disease Analyzer (DA) database, we included 4550 patients with a prescription of WS 1442 and 4550 matched patients with Tromcardin prescriptions (all registered products under the trademark Tromcardin that are magnesium and potassium supplementing foods for special medical purposes) who were followed for 5 years after the index date. The incidence of various cardiac arrhythmias (atrial fibrillation and flutter (AFF), tachycardia, and other cardiac arrhythmias) was recorded. Cox regression models were used to evaluate the potential association between both drugs and arrhythmias. The cumulative incidence of atrial fibrillation and flutter was significantly lower among patients with a prescription of WS 1442 compared to patients with magnesium\/potassium prescriptions (10.8% vs. 16.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). WS 1442 prescription was significantly associated with a lower incidence of atrial fibrillation and flutter compared to magnesium\/potassium (HR 0.71; 95% CI 0.64\u20130.80;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The cumulative incidence of tachycardia was significantly lower in the WS 1442 group compared to the magnesium\/potassium group (8.3% vs. 9.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), similarly, the cumulative incidence of other cardiac arrhythmias was significantly lower among patients with WS 1442 compared to patients with magnesium\/potassium (10.2% vs. 14.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). This study showed that in a large collective of outpatients, intake of hawthorn special extract WS 1442 was associated with a significantly lower incidence of atrial fibrillation, tachycardia, and other cardiac arrhythmias compared to magnesium\/potassium, indicating its potential in treating and preventing such conditions.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-74325-4","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:02:36Z","timestamp":1727935356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real world effectiveness of Hawthorn special extract WS 1442 in a retrospective cohort study from Germany"],"prefix":"10.1038","volume":"14","author":[{"given":"Christophe","family":"Wyss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"G\u00fcndling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"74325_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","volume":"19","author":"N Townsend","year":"2022","unstructured":"Townsend, N. et al. Epidemiology of cardiovascular disease in Europe. Nat. Rev. Cardiol. 19, 133\u2013143. https:\/\/doi.org\/10.1038\/s41569-021-00607-3 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"74325_CR2","unstructured":"Olvera Lopez, E., Ballard, B. D. & Jan, A. Cardiovascular Disease. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535419\/ (2022)."},{"key":"74325_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/HJR.0b013e328339cc99","volume":"17","author":"A Beauchamp","year":"2010","unstructured":"Beauchamp, A., Peeters, A., Tonkin, A. & Turrell, G. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review. Eur. J. Cardiovasc. Prev. Rehabil. 17, 599\u2013606. https:\/\/doi.org\/10.1097\/HJR.0b013e328339cc99 (2010).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"74325_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1142\/s0192415x05002606","volume":"33","author":"WT Chang","year":"2005","unstructured":"Chang, W. T., Dao, J. & Shao, Z. H. Hawthorn: potential roles in cardiovascular disease. Am. J. Chin. Med. 33, 1\u201310. https:\/\/doi.org\/10.1142\/s0192415x05002606 (2005).","journal-title":"Am. J. Chin. Med."},{"key":"74325_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/BF03044432","volume":"24","author":"M Tauchert","year":"1999","unstructured":"Tauchert, M., Gildor, A. & Lipinski, J. Einsatz Des Hochdosierten Crataegusextraktes WS 1442 in Der Therapie Der Herzinsuffizienz Stadium NYHA II. Herz 24, 465\u2013474 (1999).","journal-title":"Herz"},{"key":"74325_CR6","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.3390\/molecules26237266","volume":"26","author":"F Martinelli","year":"2021","unstructured":"Martinelli, F. et al. Botanical, phytochemical, anti-microbial and pharmaceutical characteristics of hawthorn (Crataegus monogyna Jacq). Rosaceae Mol. 26, 7266 (2021).","journal-title":"Rosaceae Mol."},{"key":"74325_CR7","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.3390\/nu7095361","volume":"7","author":"SF Nabavi","year":"2015","unstructured":"Nabavi, S. F. et al. Polyphenolic composition of Crataegus monogyna Jacq.: from chemistry to medical applications. Nutrients 7, 7708\u20137728. https:\/\/doi.org\/10.3390\/nu7095361 (2015).","journal-title":"Nutrients"},{"key":"74325_CR8","doi-asserted-by":"publisher","first-page":"970","DOI":"10.5152\/akd.2014.5869","volume":"15","author":"H Alp","year":"2015","unstructured":"Alp, H., Soner, B. C., Baysal, T. & Sahin, A. S. Protective effects of Hawthorn (Crataegus oxyacantha) extract against digoxin-induced arrhythmias in rats. Anatol. J. Cardiol. 15, 970\u2013975. https:\/\/doi.org\/10.5152\/akd.2014.5869 (2015).","journal-title":"Anatol. J. Cardiol."},{"key":"74325_CR9","first-page":"45","volume":"3","author":"T Krzeminski","year":"1993","unstructured":"Krzeminski, T. & Chatterjee, S. S. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharm. Pharmacol. Lett. 3, 45\u201348 (1993).","journal-title":"Pharm. Pharmacol. Lett."},{"key":"74325_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40256-017-0249-9","volume":"18","author":"CJF Holubarsch","year":"2018","unstructured":"Holubarsch, C. J. F., Colucci, W. S. & Eha, J. Benefit-risk assessment of Crataegus extract WS 1442: an evidence-based review. Am. J. Cardiovasc. Drugs 18, 25\u201336. https:\/\/doi.org\/10.1007\/s40256-017-0249-9 (2018).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"74325_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s15006-018-0725-4","volume":"160","author":"T Wegener","year":"2018","unstructured":"Wegener, T. et al. Significance of hawthorn extract in general practice\u2014a current positioning. MMW Fortschr. Med. 160, 1\u20137. https:\/\/doi.org\/10.1007\/s15006-018-0725-4 (2018).","journal-title":"MMW Fortschr. Med."},{"key":"74325_CR12","first-page":"521","volume":"68","author":"M Zorniak","year":"2017","unstructured":"Zorniak, M., Szydlo, B. & Krzeminski, T. F. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences. J. Physiol. Pharmacol. 68, 521\u2013526 (2017).","journal-title":"J. Physiol. Pharmacol."},{"key":"74325_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.26402\/jpp.2019.2.14","volume":"70","author":"M Zorniak","year":"2019","unstructured":"Zorniak, M., Porc, M. P. & Krzeminski, T. F. Hawthorn revisited: time- and dose-dependent cardioprotective action of WS-1442 special extract in the reperfusion-induced arrhythmia model in rats in vivo. J. Physiol. Pharmacol. 70, 14. https:\/\/doi.org\/10.26402\/jpp.2019.2.14 (2019).","journal-title":"J. Physiol. Pharmacol."},{"issue":"Suppl 1","key":"74325_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000080574","volume":"11","author":"M Habs","year":"2004","unstructured":"Habs, M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. Forsch. Komplementarmed Klass Nat. 11 (Suppl 1), 36\u201339. https:\/\/doi.org\/10.1159\/000080574 (2004).","journal-title":"Forsch. Komplementarmed Klass Nat."},{"key":"74325_CR15","first-page":"159","volume":"147","author":"M Koller","year":"2005","unstructured":"Koller, M. et al. Wei\u00dfdorn-Spezialextrakt in Der Therapie fr\u00fcher Stadien Der KHK-assoziierten Herzinsuffizienz. Ergebnisse Einer Prospektiven Kohortenstudie Zur Wirtschaftlichkeit Und Zum Einfluss auf die Lebensqualit\u00e4t Der Patienten. MMW Fortschr. Med. 147, 159\u2013164 (2005).","journal-title":"MMW Fortschr. Med."},{"key":"74325_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.phymed.2011.06.022","volume":"18","author":"T Eggeling","year":"2011","unstructured":"Eggeling, T., Regitz-Zagrosek, V., Zimmermann, A. & Burkart, M. Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure\u2014a pooled analysis of clinical trials. Phytomedicine 18, 1214\u20131219. https:\/\/doi.org\/10.1016\/j.phymed.2011.06.022 (2011).","journal-title":"Phytomedicine"},{"key":"74325_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1081\/ceh-200044275","volume":"27","author":"W Weglicki","year":"2005","unstructured":"Weglicki, W., Quamme, G., Tucker, K., Haigney, M. & Resnick, L. Potassium, magnesium, and electrolyte imbalance and complications in disease management. Clin. Exp. Hypertens. 27, 95\u2013112. https:\/\/doi.org\/10.1081\/ceh-200044275 (2005).","journal-title":"Clin. Exp. Hypertens."},{"key":"74325_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/cp203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann, W., Bongaerts, B., Carius, H. J., Kruppert, S. & Kostev, K. Basic characteristics and representativeness of the German Disease Analyzer database. Int. J. Clin. Pharmacol. Ther. 56, 459\u2013466. https:\/\/doi.org\/10.5414\/cp203320 (2018).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"74325_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1067\/mhj.2002.121463","volume":"143","author":"M Tauchert","year":"2002","unstructured":"Tauchert, M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am. Heart J. 143, 910\u2013915. https:\/\/doi.org\/10.1067\/mhj.2002.121463 (2002).","journal-title":"Am. Heart J."},{"key":"74325_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ejheart.2008.10.004","volume":"10","author":"CJF Holubarsch","year":"2008","unstructured":"Holubarsch, C. J. F., Colucci, W. S., Meinertz, T., Gaus, W. & Tendera, M. The efficacy and safety of Crataegus extract WS\u00ae 1442 in patients with heart failure: the SPICE trial. Eur. J. Heart Fail. 10, 1255\u20131263. https:\/\/doi.org\/10.1016\/j.ejheart.2008.10.004 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"74325_CR21","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/eurjhf\/hfp116","volume":"11","author":"SM Zick","year":"2009","unstructured":"Zick, S. M., Vautaw, B. M., Gillespie, B. & Aaronson, K. D. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial. Eur. J. Heart Fail. 11, 990\u2013999. https:\/\/doi.org\/10.1093\/eurjhf\/hfp116 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"74325_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.phymed.2006.01.005","volume":"13","author":"SR Long","year":"2006","unstructured":"Long, S. R., Carey, R. A., Crofoot, K. M., Proteau, P. J. & Filtz, T. M. Effect of hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine 13, 643\u2013650. https:\/\/doi.org\/10.1016\/j.phymed.2006.01.005 (2006).","journal-title":"Phytomedicine"},{"key":"74325_CR23","doi-asserted-by":"publisher","unstructured":"Hindricks, G. et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task torce for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612 (2021).","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"74325_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phymed.2011.08.059","volume":"19","author":"E Rieckeheer","year":"2011","unstructured":"Rieckeheer, E., Schwinger, R. H., Bloch, W. & Brixius, K. Hawthorn special extract WS\u00ae 1442 increases red blood cell NO-formation without altering red blood cell deformability. Phytomedicine 19, 20\u201324. https:\/\/doi.org\/10.1016\/j.phymed.2011.08.059 (2011).","journal-title":"Phytomedicine"},{"key":"74325_CR25","first-page":"1157","volume":"45","author":"S P\u00f6pping","year":"1995","unstructured":"P\u00f6pping, S., Rose, H., Ionescu, I., Fischer, Y. & Kammermeier, H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 45, 1157\u20131161 (1995).","journal-title":"Arzneimittelforschung"},{"key":"74325_CR26","first-page":"1261","volume":"45","author":"G Joseph","year":"1995","unstructured":"Joseph, G., Zhao, Y. & Klaus, W. Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart. Arzneimittelforschung 45, 1261\u20131265 (1995).","journal-title":"Arzneimittelforschung"},{"key":"74325_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-1999-13997","volume":"65","author":"A M\u00fcller","year":"1999","unstructured":"M\u00fcller, A., Linke, W. & Klaus, W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med. 65, 335\u2013339. https:\/\/doi.org\/10.1055\/s-1999-13997 (1999).","journal-title":"Planta Med."},{"key":"74325_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","volume":"12","author":"YF Hu","year":"2015","unstructured":"Hu, Y. F., Chen, Y. J., Lin, Y. J. & Chen, S. A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230\u2013243. https:\/\/doi.org\/10.1038\/nrcardio.2015.2 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"74325_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/FJC.0b013e31817f9398","volume":"52","author":"DR Van Wagoner","year":"2008","unstructured":"Van Wagoner, D. R. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J. Cardiovasc. Pharmacol. 52, 306\u2013313. https:\/\/doi.org\/10.1097\/FJC.0b013e31817f9398 (2008).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"74325_CR30","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.lfs.2003.09.050","volume":"74","author":"M Veveris","year":"2004","unstructured":"Veveris, M., Koch, E. & Chatterjee, S. S. Crataegus special extract WS\u00ae 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci. 74, 1945\u20131955. https:\/\/doi.org\/10.1016\/j.lfs.2003.09.050 (2004).","journal-title":"Life Sci."},{"key":"74325_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/sports2030059","volume":"2","author":"S H\u00e4rtel","year":"2014","unstructured":"H\u00e4rtel, S. et al. Effects of endurance exercise training and Crataegus extract WS\u00ae 1442 in patients with heart failure with preserved ejection fraction\u2014a randomized controlled trial. Sports 2, 59\u201375. https:\/\/doi.org\/10.3390\/sports2030059 (2014).","journal-title":"Sports"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74325-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:10:38Z","timestamp":1727935838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74325-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74325"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74325-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4436156\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CW received speakers fee from Dr. Willmar Schwabe GmbH & Co. KG, Novartis, Medtronic, Abbott, Sanofi, and Daiichi Sankyo in the past. PWG received speaker\u2019s fees from Dr. Willmar Schwabe GmbH & Co. KG in the past. KK declares to have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22986"}}